Clinical trial · Interventional
A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.
NCT01929421CI-TRIAL-00032854completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the efficacy and safety of salvage tratment with Gemcitabine and S-1 Combination in metastatic colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine/S-1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gemcitabine/ s-1
- interventionNames
- Drug: Gemcitabine/S-1
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 1year
Secondary outcomes (2)
- measure
- overall survival
- timeFrame
- 1year
- measure
- number of participants with adverse events
- timeFrame
- 1year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * non resectable colorectal adenocarcinoma. * disease progression during or within 6months after treatment with irinotecan and oxaliplatin contaning regimens. * estimated life expectancy of more than 3 months. * ECOG status 2 or lower Exclusion Criteria: * other tumor type than adenoarcinoma. * presence or history of CNS metastasis. * evidence of gastrointestinal bleeding.
References
Publications (0)
Data not yet available
No reference posted for this study.